HomeCompareEMB vs ABBV

EMB vs ABBV: Dividend Comparison 2026

EMB yields 5.14% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $76.7K in total portfolio value
10 years
EMB
EMB
● Live price
5.14%
Share price
$93.11
Annual div
$4.78
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$713.45
Full EMB calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — EMB vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMB
Annual income on $10K today (after 15% tax)
$436.65/yr
After 10yr DRIP, annual income (after tax)
$606.43/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,260.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMB + ABBV for your $10,000?

EMB: 50%ABBV: 50%
100% ABBV50/50100% EMB
Portfolio after 10yr
$66.4K
Annual income
$13,219.58/yr
Blended yield
19.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EMB
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMB buys
0
ABBV buys
0
No recent congressional trades found for EMB or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMBABBV
Forward yield5.14%3.12%
Annual dividend / share$4.78$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$28.0K$104.7K
Annual income after 10y$713.45$25,725.73
Total dividends collected$6.2K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EMB vs ABBV ($10,000, DRIP)

YearEMB PortfolioEMB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,214$513.71$11,559$438.51$345.00ABBV
2$12,537$538.37$13,494$640.86$957.00ABBV
3$13,977$562.53$15,951$945.97$2.0KABBV
4$15,542$586.12$19,152$1,413.89$3.6KABBV
5$17,239$609.09$23,443$2,146.38$6.2KABBV
6$19,077$631.40$29,391$3,321.96$10.3KABBV
7$21,065$653.01$37,948$5,265.87$16.9KABBV
8$23,214$673.90$50,795$8,596.74$27.6KABBV
9$25,533$694.05$71,034$14,549.41$45.5KABBV
10$28,033$713.45$104,715$25,725.73$76.7KABBV

EMB vs ABBV: Complete Analysis 2026

EMBStock

The iShares J.P. Morgan USD Emerging Markets Bond ETF seeks to track the investment results of an index composed of U.S. dollar-denominated, emerging market bonds.

Full EMB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EMB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMB vs SCHDEMB vs JEPIEMB vs OEMB vs KOEMB vs MAINEMB vs JNJEMB vs MRKEMB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.